Abstract:Stroke remains one of the main causes of mortality and morbidity worldwide. Immediately after stroke, a neuroinflammatory process starts in the brain, triggering a systemic immunodepression mainly through excessive activation of the autonomous nervous system. Manifestations of immunodepression include lymphopenia but also dysfunctional innate and adaptive immune cells. The resulting impaired antibacterial defenses render patients with stroke susceptible to infections. In addition, other risk factors like stroke severity, dysphagia, impaired consciousness, mechanical ventilation, catheterization, and older age predispose stroke patients for infections. Most common infections are pneumonia and urinary tract infection, both occur in ≈10% of the patients. Especially pneumonia increases unfavorable outcome and mortality in patients with stroke; systemic effects like hypotension, fever, delay in rehabilitation are thought to play a crucial role. Experimental and clinical data suggest that systemic infections enhance autoreactive immune responses against brain antigens and thus negatively affect outcome but convincing evidence is lacking. Prevention of poststroke infections by preventive antibiotic therapy did not improve functional outcome after stroke. Immunomodulatory approaches counteracting immunodepression to prevent stroke-associated pneumonia need to account for neuroinflammation in the ischemic brain and avoid further tissue damage. Experimental studies discovered interesting targets, but these have not yet been investigated in patients with stroke. A better understanding of the pathobiology may help to develop optimized approaches of preventive antibiotic therapy or immunomodulation to effectively prevent stroke-associated pneumonia while improving long-term outcome after stroke. In this review, we aim to characterize epidemiology, risk factors, cause, diagnosis, clinical presentation, and potential treatment of poststroke immunosuppression and associated infections.

Immunothrombosis in Acute Ischemic Stroke

Systemic immune responses after ischemic stroke: From the center to the periphery

Contribution of the immune response to stroke provides promising directions for future stroke immunotherapies

Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke

Immunoreactive Cells after Cerebral Ischemia

Thrombo-Inflammation and Immunological Response in Ischemic Stroke: Focusing on Platelet-Tregs Interaction

Neurovascular Inflammation and Complications of Thrombolysis Therapy in Stroke

The role of T cells in acute ischemic stroke

The Role of Thrombo-inflammation in Ischemic Stroke: Focus on the Manipulation and Clinical Application

Glial Cells: Role of the Immune Response in Ischemic Stroke

63. Immune Response in Acute Ischaemic Stroke

T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights

Mechanism and application of immune interventions in intracerebral haemorrhage

Immune Cells in the BBB Disruption After Acute Ischemic Stroke: Targets for Immune Therapy?

Inflammatory mechanisms in ischemic stroke: therapeutic approaches

The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy

Focused Update on Stroke Neuroimmunology: Current Progress in Preclinical and Clinical Research and Recent Mechanistic Insight.

Immunodepression, Infections, and Functional Outcome in Ischemic Stroke.

Mechanisms of immune response and cell death in ischemic stroke and their regulation by natural compounds

Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'

Platelets as Modulators of Cerebral Ischemia/Reperfusion Injury